The company was founded in 2014 by Dr. Ralf Hilfrich (technical director) and Stefan Raupach (commercial director) with the vision to establish a new cancer screening program for the early detection of HPV-induced mouth and throat cancer. The two founders combine more than 40 years of experience in the development, manufacturing and marketing of in-vitro diagnostics. Located in Ammersbek near Hamburg, the company distributes the rapid test since 2015 to dentists, dermatologists and other specialists, who offer cancer prevention services to their patients.
AYOXXA has developed a technology platform opening multiplexed protein analysis in biomedical research, pharmacological screening, and preclinical diagnostics development.
Lophius Biosciences GmbH is a privately-held biotech company specialized on the development and marketing of innovative T cell-based research tools, contract research solutions and diagnostics using the ELISpot technology for the functional assessment of pathogen-reactive T cells.
Lophius’ experts provide a comprehensive range of services from antigen selection and optimization to immune assay development and therapy monitoring under ISO 9001 quality standards. The continuously expanding portfolio of research tools supports highly standardized and convenient experimental procedures in clinical laboratories.
Combined with Lophius’ immunological expertise to develop diagnostic systems, the company has proven its capabilities by the development and launch of the CE-marked in vitro diagnostic solution T-Track® CMV. Produced in compliance with ISO 13485 quality standards, T-Track® CMV is intended to optimize CMV therapy management in transplant patients.
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic methods. The first product, based on the quantification of microRNA, is a blood test for the detection of testicular cancer. The high sensitivity and accuracy of the test improves the diagnosis and therapy of patients significantly and reduces the costs for the health care system. miRdetect has developed a patented platform technology, which allows the exact and reliable quantification of small amounts of genetic material in body fluids. This robust method represents the basis for the development of additional diagnostic tests.
A well-rounded life science company, OakLabs' singular goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx) and development of IEC 62304 compliant medical device software.
The skilled team of quantum physicists and biochemists at OakLabs have revitalized the process of drug development with a new and efficient approach to patient selection in clinical trials. Their groundbreaking technique entails the use of an innovative algorithm to develop complex biomarker signatures which can accurately predict (non-)responders for specific drugs with superior accuracy. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.
oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
Predemtec develops a blood test for the diagnosis of Alzheimer’s disease (AD). For the first time a reliable and affordable kit for the diagnosis of Alzheimer gets available.